Polypeptide Delivery Platform
PLL THERAPEUTICS
Our technology is based on creating Poly-L-Lysine conjugate with active compounds which allow them to increase their shelflife in the body, allow them to go through the Brain Blood barrier (BBB) and to distribute the compound in the cell directly.
Our DP, PLys® (Poly-L-Lysine) is a drug carrier with best-in-class properties conjugating stability, high internalization and no immunogenicity.
STRUCTURE
FORMULATION
INTERNALIZATION (1,3,4)
Poly-L-Lysine Action with Molecular Dynamics by AI – How our DP release our API SCFAs in the Cell
The 70-unit Poly-L-Lysine are soluble in water with more or less local folding according to the conjugate.
When the conjugates are water soluble the nanomolecular object stays in water.
When the conjugates are lipophilic as our SCFAs the nano-object anchors to the biological membranes.
Poly-L-Lysine conjugate with SCFAs
Molecular dynamics simulations allow sampling all intermolecular movements to accurately support Poly-L-Lysine mechanism and localization of action
How is internalized ?
Example of Parkinson origins…looks like ALS origins
- As shown previously with ALS, pro–inflammatory molecules can reach blood circulation through permeabilisation of gut barriers.
- These pro-inflammatory molecules can damaged neuron cells and forms protein aggregates in the brain that’s lead to brain degenerescence.
- Poly-L-Lysine solution target these pro-inflammatory molecules to inhibit the degenerescence process.
- Poly-L-Lysine have a positive impact in each inflammatory/neurodegenerative disease wich this pathway is involed in the origins of the disease.